BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One 2015;10:e0141082. [PMID: 26539823 DOI: 10.1371/journal.pone.0141082] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
Number Citing Articles
1 Cirino G, Szabo C, Papapetropoulos A. Physiological roles of hydrogen sulfide in mammalian cells, tissues and organs. Physiological Reviews. [DOI: 10.1152/physrev.00028.2021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
2 Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: modulators and therapeutic targets in liver inflammation. Semin Immunopathol 2022. [PMID: 35415765 DOI: 10.1007/s00281-022-00935-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
3 Ishimwe JA, Dola T, Ertuglu LA, Kirabo A. Bile Acids and Salt-sensitive Hypertension: A Role of the Gut-liver Axis. Am J Physiol Heart Circ Physiol 2022. [PMID: 35245132 DOI: 10.1152/ajpheart.00027.2022] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Fiorucci S, Distrutti E. Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med 2022;28:51-66. [PMID: 34815180 DOI: 10.1016/j.molmed.2021.10.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
5 Fiorillo B, Sepe V, Conflitti P, Roselli R, Biagioli M, Marchianò S, De Luca P, Baronissi G, Rapacciuolo P, Cassiano C, Catalanotti B, Zampella A, Limongelli V, Fiorucci S. Structural Basis for Developing Multitarget Compounds Acting on Cysteinyl Leukotriene Receptor 1 and G-Protein-Coupled Bile Acid Receptor 1. J Med Chem 2021;64:16512-29. [PMID: 34767347 DOI: 10.1021/acs.jmedchem.1c01078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Biagioli M, Fiorucci S. Bile acid activated receptors: Integrating immune and metabolic regulation in non-alcoholic fatty liver disease. Liver Research 2021;5:119-41. [DOI: 10.1016/j.livres.2021.08.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
8 Ma K, Tang D, Yu C, Zhao L. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol 2021;56:717-26. [PMID: 33771073 DOI: 10.1080/00365521.2021.1903547] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Ganguly A, Ofman G, Vitiello PF. Hydrogen Sulfide-Clues from Evolution and Implication for Neonatal Respiratory Diseases. Children (Basel) 2021;8:213. [PMID: 33799529 DOI: 10.3390/children8030213] [Reference Citation Analysis]
10 Fiorucci S, Distrutti E, Carino A, Zampella A, Biagioli M. Bile acids and their receptors in metabolic disorders. Prog Lipid Res 2021;82:101094. [PMID: 33636214 DOI: 10.1016/j.plipres.2021.101094] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 47.0] [Reference Citation Analysis]
11 Carino A, Marchianò S, Biagioli M, Scarpelli P, Bordoni M, Di Giorgio C, Roselli R, Fiorucci C, Monti MC, Distrutti E, Zampella A, Fiorucci S. The bile acid activated receptors GPBAR1 and FXR exert antagonistic effects on autophagy. FASEB j 2021;35. [DOI: 10.1096/fj.202001386r] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Howlett-Prieto Q, Langer C, Rezania K, Soliven B. Modulation of immune responses by bile acid receptor agonists in myasthenia gravis. J Neuroimmunol 2020;349:577397. [PMID: 32979707 DOI: 10.1016/j.jneuroim.2020.577397] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Portincasa P, Di Ciaula A, Garruti G, Vacca M, De Angelis M, Wang DQ. Bile Acids and GPBAR-1: Dynamic Interaction Involving Genes, Environment and Gut Microbiome. Nutrients 2020;12:E3709. [PMID: 33266235 DOI: 10.3390/nu12123709] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
14 Holter MM, Chirikjian MK, Govani VN, Cummings BP. TGR5 Signaling in Hepatic Metabolic Health. Nutrients 2020;12:E2598. [PMID: 32859104 DOI: 10.3390/nu12092598] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
15 Perino A, Demagny H, Velazquez-Villegas L, Schoonjans K. Molecular Physiology of Bile Acid Signaling in Health, Disease, and Aging. Physiol Rev 2021;101:683-731. [PMID: 32790577 DOI: 10.1152/physrev.00049.2019] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 32.0] [Reference Citation Analysis]
16 Keitel V, Gertzen CGW, Schäfer S, Klindt C, Wöhler C, Deutschmann K, Reich M, Gohlke H, Häussinger D. Bile Acids and TGR5 (Gpbar1) Signaling. In: Rozman D, Gebhardt R, editors. Mammalian Sterols. Cham: Springer International Publishing; 2020. pp. 81-100. [DOI: 10.1007/978-3-030-39684-8_4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Holter MM, Chirikjian MK, Briere DA, Maida A, Sloop KW, Schoonjans K, Cummings BP. Compound 18 Improves Glucose Tolerance in a Hepatocyte TGR5-dependent Manner in Mice. Nutrients 2020;12:E2124. [PMID: 32708970 DOI: 10.3390/nu12072124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
18 Merlen G, Bidault‐jourdainne V, Kahale N, Glenisson M, Ursic‐bedoya J, Doignon I, Garcin I, Humbert L, Rainteau D, Tordjmann T. Hepatoprotective impact of the bile acid receptor TGR5. Liver Int 2020;40:1005-15. [DOI: 10.1111/liv.14427] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 6.5] [Reference Citation Analysis]
19 Biagioli M, Carino A, Fiorucci C, Marchianò S, Di Giorgio C, Bordoni M, Roselli R, Baldoni M, Distrutti E, Zampella A, Fiorucci S. The Bile Acid Receptor GPBAR1 Modulates CCL2/CCR2 Signaling at the Liver Sinusoidal/Macrophage Interface and Reverses Acetaminophen-Induced Liver Toxicity. J Immunol 2020;204:2535-51. [PMID: 32213564 DOI: 10.4049/jimmunol.1901427] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
20 Keitel V, Gertzen CG, Spomer L, Gohlke H, Häussinger D. TGR5 (GPBAR1) in the Liver. The Liver 2020. [DOI: 10.1002/9781119436812.ch24] [Reference Citation Analysis]
21 Klindt C, Reich M, Hellwig B, Stindt J, Rahnenführer J, Hengstler JG, Köhrer K, Schoonjans K, Häussinger D, Keitel V. The G Protein-Coupled Bile Acid Receptor TGR5 (Gpbar1) Modulates Endothelin-1 Signaling in Liver. Cells 2019;8:E1467. [PMID: 31752395 DOI: 10.3390/cells8111467] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
22 Keitel V, Stindt J, Häussinger D. Bile Acid-Activated Receptors: GPBAR1 (TGR5) and Other G Protein-Coupled Receptors. Handb Exp Pharmacol 2019;256:19-49. [PMID: 31302759 DOI: 10.1007/164_2019_230] [Cited by in Crossref: 48] [Cited by in F6Publishing: 26] [Article Influence: 16.0] [Reference Citation Analysis]
23 Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. J Hepatol 2019;71:1126-40. [PMID: 31295531 DOI: 10.1016/j.jhep.2019.06.017] [Cited by in Crossref: 89] [Cited by in F6Publishing: 74] [Article Influence: 29.7] [Reference Citation Analysis]
24 Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. Intestinal mucus and gut-vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosis.. [DOI: 10.1101/690057] [Reference Citation Analysis]
25 Schierwagen R, Klein S, Uschner F, Trebicka J. Novel Targets and Drug Development in Portal Hypertension. Curr Hepatology Rep 2019;18:187-196. [DOI: 10.1007/s11901-019-00462-4] [Reference Citation Analysis]
26 Li G, Jiang Q, Xu K. CREB family: A significant role in liver fibrosis. Biochimie 2019;163:94-100. [PMID: 31112743 DOI: 10.1016/j.biochi.2019.05.014] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
27 Majumder S, Ren L, Pushpakumar S, Sen U. Hydrogen sulphide mitigates homocysteine-induced apoptosis and matrix remodelling in mesangial cells through Akt/FOXO1 signalling cascade. Cell Signal 2019;61:66-77. [PMID: 31085234 DOI: 10.1016/j.cellsig.2019.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
28 Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int. 2019;39:598-609. [PMID: 30312513 DOI: 10.1111/liv.13986] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
29 Carino A, Marchianò S, Biagioli M, Bucci M, Vellecco V, Brancaleone V, Fiorucci C, Zampella A, Monti MC, Distrutti E, Fiorucci S. Agonism for the bile acid receptor GPBAR1 reverses liver and vascular damage in a mouse model of steatohepatitis. FASEB J 2019;33:2809-22. [PMID: 30303744 DOI: 10.1096/fj.201801373RR] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
30 Sbodio JI, Snyder SH, Paul BD. Regulators of the transsulfuration pathway. Br J Pharmacol 2019;176:583-93. [PMID: 30007014 DOI: 10.1111/bph.14446] [Cited by in Crossref: 107] [Cited by in F6Publishing: 115] [Article Influence: 26.8] [Reference Citation Analysis]
31 Arab JP, Barrera F, Arrese M. Bile Acids and Portal Hypertension. Ann Hepatol 2017;16:s83-6. [PMID: 29080345 DOI: 10.5604/01.3001.0010.5500] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
32 Pajares MA, Pérez-Sala D. Mammalian Sulfur Amino Acid Metabolism: A Nexus Between Redox Regulation, Nutrition, Epigenetics, and Detoxification. Antioxid Redox Signal 2018;29:408-52. [PMID: 29186975 DOI: 10.1089/ars.2017.7237] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
33 Carino A, Cipriani S, Marchianò S, Biagioli M, Scarpelli P, Zampella A, Monti MC, Fiorucci S. Gpbar1 agonism promotes a Pgc-1α-dependent browning of white adipose tissue and energy expenditure and reverses diet-induced steatohepatitis in mice. Sci Rep 2017;7:13689. [PMID: 29057935 DOI: 10.1038/s41598-017-13102-y] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
34 Liu S, Yi F, Cheng W, Qu X, Wang C. Molecular mechanisms in vascular injury induced by hypertension: Expression and role of microRNA-34a. Exp Ther Med 2017;14:5497-502. [PMID: 29285082 DOI: 10.3892/etm.2017.5216] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
35 Li G, Peng Y, Zhao T, Lin J, Duan X, Wei Y, Ma J. Plumbagin Alleviates Capillarization of Hepatic Sinusoids In Vitro by Downregulating ET-1, VEGF, LN, and Type IV Collagen. Biomed Res Int 2017;2017:5603216. [PMID: 28770223 DOI: 10.1155/2017/5603216] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Yuan S, Shen X, Kevil CG. Beyond a Gasotransmitter: Hydrogen Sulfide and Polysulfide in Cardiovascular Health and Immune Response. Antioxid Redox Signal 2017;27:634-53. [PMID: 28398086 DOI: 10.1089/ars.2017.7096] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 12.6] [Reference Citation Analysis]
37 Chen S, Sun P, Zhao X, Yi R, Qian J, Shi Y, Wang R. Gardenia jasminoides has therapeutic effects on L‑NNA‑induced hypertension in vivo. Mol Med Rep 2017;15:4360-73. [PMID: 28487985 DOI: 10.3892/mmr.2017.6542] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
38 Carino A, Cipriani S, Marchianò S, Biagioli M, Santorelli C, Donini A, Zampella A, Monti MC, Fiorucci S. BAR502, a dual FXR and GPBAR1 agonist, promotes browning of white adipose tissue and reverses liver steatosis and fibrosis. Sci Rep 2017;7:42801. [PMID: 28202906 DOI: 10.1038/srep42801] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 14.0] [Reference Citation Analysis]
39 Fiorucci S, Zampella A, Cirino G, Bucci M, Distrutti E. Decoding the vasoregulatory activities of bile acid-activated receptors in systemic and portal circulation: role of gaseous mediators. Am J Physiol Heart Circ Physiol. 2017;312:H21-H32. [PMID: 27765751 DOI: 10.1152/ajpheart.00577.2016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
40 Fiorucci S, Distrutti E. Targeting the transsulfuration-H2S pathway by FXR and GPBAR1 ligands in the treatment of portal hypertension. Pharmacol Res 2016;111:749-56. [PMID: 27475883 DOI: 10.1016/j.phrs.2016.07.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
41 Finamore C, Festa C, Renga B, Sepe V, Carino A, Masullo D, Biagioli M, Marchianò S, Capolupo A, Monti MC, Fiorucci S, Zampella A. Navigation in bile acid chemical space: discovery of novel FXR and GPBAR1 ligands. Sci Rep 2016;6:29320. [PMID: 27381677 DOI: 10.1038/srep29320] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]